JP2014530611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530611A5 JP2014530611A5 JP2014535927A JP2014535927A JP2014530611A5 JP 2014530611 A5 JP2014530611 A5 JP 2014530611A5 JP 2014535927 A JP2014535927 A JP 2014535927A JP 2014535927 A JP2014535927 A JP 2014535927A JP 2014530611 A5 JP2014530611 A5 JP 2014530611A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bms2h
- gly
- antibody polypeptide
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546800P | 2011-10-13 | 2011-10-13 | |
| US61/546,800 | 2011-10-13 | ||
| US201261655110P | 2012-06-04 | 2012-06-04 | |
| US61/655,110 | 2012-06-04 | ||
| PCT/US2012/059977 WO2013056068A1 (en) | 2011-10-13 | 2012-10-12 | Antibody polypeptides that antagonize cd40l |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530611A JP2014530611A (ja) | 2014-11-20 |
| JP2014530611A5 true JP2014530611A5 (https=) | 2015-10-29 |
| JP6163158B2 JP6163158B2 (ja) | 2017-07-12 |
Family
ID=47046896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535927A Active JP6163158B2 (ja) | 2011-10-13 | 2012-10-12 | Ｃｄ４０ｌに拮抗する抗体ポリペプチド |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US8895010B2 (https=) |
| EP (1) | EP2766395B1 (https=) |
| JP (1) | JP6163158B2 (https=) |
| KR (1) | KR101637915B1 (https=) |
| CN (1) | CN104245732B (https=) |
| AR (1) | AR088455A1 (https=) |
| AU (2) | AU2012322093C1 (https=) |
| BR (1) | BR112014009069A2 (https=) |
| CA (1) | CA2851814C (https=) |
| CL (1) | CL2014000958A1 (https=) |
| CO (1) | CO7020864A2 (https=) |
| CY (1) | CY1123618T1 (https=) |
| DK (1) | DK2766395T3 (https=) |
| EA (1) | EA030852B1 (https=) |
| ES (1) | ES2769806T3 (https=) |
| HR (1) | HRP20200230T1 (https=) |
| HU (1) | HUE048365T2 (https=) |
| IL (1) | IL231925B (https=) |
| LT (1) | LT2766395T (https=) |
| MX (1) | MX357231B (https=) |
| PE (1) | PE20141478A1 (https=) |
| PL (1) | PL2766395T3 (https=) |
| PT (1) | PT2766395T (https=) |
| RS (1) | RS60021B1 (https=) |
| SG (2) | SG10201610288TA (https=) |
| SI (1) | SI2766395T1 (https=) |
| SM (1) | SMT202000091T1 (https=) |
| TW (1) | TWI585102B (https=) |
| UY (1) | UY34394A (https=) |
| WO (1) | WO2013056068A1 (https=) |
| ZA (1) | ZA201402603B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| US20140106405A1 (en) * | 2012-10-15 | 2014-04-17 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN106132429A (zh) | 2014-03-19 | 2016-11-16 | 百时美施贵宝公司 | 使用针对cd40l的域抗体治疗移植物排斥的方法 |
| CN104090115B (zh) * | 2014-07-10 | 2016-01-13 | 上海益诺思生物技术有限公司 | 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法 |
| CN106687133A (zh) * | 2014-09-10 | 2017-05-17 | 百时美施贵宝公司 | 使用针对cd40l的域抗体治疗自身免疫性疾病的方法 |
| KR101760707B1 (ko) * | 2015-01-05 | 2017-07-24 | 한림대학교 산학협력단 | 이종 알부민을 이용한 장기 이식 거부반응 검사용 키트 |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| KR101752280B1 (ko) | 2015-03-31 | 2017-06-30 | 서울대학교산학협력단 | 영장류 cd154에 특이적인 항체 및 이를 생산하는 융합 세포주 |
| CA2991634C (en) * | 2015-07-16 | 2026-03-17 | Inhibrx Biosciences, Inc. | Multivalent and multispecific dr5-binding fusion proteins |
| UA123398C2 (uk) | 2015-08-05 | 2021-03-31 | Янссен Байотек, Інк. | Виділене антагоністичне антитіло, яке специфічно зв'язує cd154, та фармацевтична композиція, яка його містить |
| BR112018006251A2 (pt) | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso |
| WO2017083224A1 (en) | 2015-11-09 | 2017-05-18 | Bristol-Myers Squibb Company | Methods to manipulate quality attributes of polypeptides produced in cho cells |
| CN105353135A (zh) * | 2015-11-23 | 2016-02-24 | 中国人民解放军第三军医大学第一附属医院 | 阿尔茨海默病标志物的用途 |
| KR20180080337A (ko) | 2015-11-27 | 2018-07-11 | 아블린쓰 엔.브이. | Ｃｄ40ｌ을 억제하는 폴리펩티드 |
| WO2017160975A1 (en) * | 2016-03-16 | 2017-09-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| TWI767915B (zh) | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN106967171B (zh) * | 2017-02-23 | 2021-04-27 | 郑州大学 | 一种全人源重组CD40L单抗Fab片段及其制备方法 |
| US11440951B2 (en) | 2017-03-13 | 2022-09-13 | The Government Of The United States, As Represented By The Secretary Of The Army | Therapeutic antibodies to Marburg virus |
| KR102840867B1 (ko) | 2017-05-24 | 2025-07-30 | 에이엘에스 테라피 디벨럽먼트 인스티튜트 | 치료용 항-cd40 리간드 항체 |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| RS66218B1 (sr) | 2019-07-01 | 2024-12-31 | Tonix Pharma Ltd | Anti-cd154 antitela i njihove upotrebe |
| JP2022540187A (ja) * | 2019-07-08 | 2022-09-14 | プロジェン・カンパニー・リミテッド | 新規融合タンパク質及びその用途 |
| US20210032356A1 (en) * | 2019-08-02 | 2021-02-04 | Eastern Virginia Medical School | Method for treating seizures |
| WO2021113648A1 (en) * | 2019-12-06 | 2021-06-10 | The University Of North Carolina At Chapel Hill | Affinity molecules that direct the metabolism and polarization of macrophages and synergize the immune checkpoint blockade therapy |
| KR20210095781A (ko) * | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| WO2022150452A1 (en) | 2021-01-06 | 2022-07-14 | Seth Lederman | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| WO2024249042A2 (en) * | 2023-05-26 | 2024-12-05 | Vanderbilt University | Human monoclonal antibodies for human parainfluenza virus type 3 |
| WO2025248134A1 (en) | 2024-05-31 | 2025-12-04 | Tonix Pharma Limited | Treatment methods comprising administration of modified cd154 antibodies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| EP1639014B1 (en) | 2003-06-13 | 2010-09-22 | Biogen Idec MA Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| CN1835976B (zh) * | 2003-06-13 | 2012-06-13 | 比奥根艾迪克Ma公司 | 无糖基抗-cd154(cd40配体)抗体及其用途 |
| DE602004017726D1 (de) * | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| CN101443043A (zh) * | 2003-10-08 | 2009-05-27 | 杜门蒂斯有限公司 | 抗体组合物和方法 |
| CN101061140B (zh) * | 2004-09-17 | 2015-07-01 | 多曼蒂斯有限公司 | 单价结合cd40l的组合物和应用方法 |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| JP2008535841A (ja) | 2005-04-06 | 2008-09-04 | ブリストル−マイヤーズ スクイブ カンパニー | 可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法 |
| US8476239B2 (en) | 2005-12-20 | 2013-07-02 | Bristol-Myers Squibb Company | Stable protein formulations |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| ME00832B (me) * | 2007-03-22 | 2012-03-20 | Ucb Biopharma Sprl | Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba |
| GB0815788D0 (en) * | 2008-08-29 | 2008-10-08 | Isis Innovation | Therapeutic antibodies |
| HUE049849T2 (hu) | 2010-03-31 | 2020-10-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| HUE038848T2 (hu) | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
| SMT202000091T1 (it) * | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| CN106132429A (zh) | 2014-03-19 | 2016-11-16 | 百时美施贵宝公司 | 使用针对cd40l的域抗体治疗移植物排斥的方法 |
-
2012
- 2012-10-11 SM SM20200091T patent/SMT202000091T1/it unknown
- 2012-10-12 LT LTEP12775423.2T patent/LT2766395T/lt unknown
- 2012-10-12 EA EA201490745A patent/EA030852B1/ru not_active IP Right Cessation
- 2012-10-12 RS RS20200157A patent/RS60021B1/sr unknown
- 2012-10-12 ES ES12775423T patent/ES2769806T3/es active Active
- 2012-10-12 KR KR1020147012398A patent/KR101637915B1/ko active Active
- 2012-10-12 SG SG10201610288TA patent/SG10201610288TA/en unknown
- 2012-10-12 US US13/650,493 patent/US8895010B2/en active Active
- 2012-10-12 SI SI201231719T patent/SI2766395T1/sl unknown
- 2012-10-12 CA CA2851814A patent/CA2851814C/en not_active Expired - Fee Related
- 2012-10-12 DK DK12775423.2T patent/DK2766395T3/da active
- 2012-10-12 AR ARP120103816A patent/AR088455A1/es unknown
- 2012-10-12 SG SG11201401385YA patent/SG11201401385YA/en unknown
- 2012-10-12 TW TW101137824A patent/TWI585102B/zh not_active IP Right Cessation
- 2012-10-12 PL PL12775423T patent/PL2766395T3/pl unknown
- 2012-10-12 PE PE2014000522A patent/PE20141478A1/es active IP Right Grant
- 2012-10-12 EP EP12775423.2A patent/EP2766395B1/en active Active
- 2012-10-12 JP JP2014535927A patent/JP6163158B2/ja active Active
- 2012-10-12 HR HRP20200230TT patent/HRP20200230T1/hr unknown
- 2012-10-12 AU AU2012322093A patent/AU2012322093C1/en not_active Ceased
- 2012-10-12 BR BR112014009069-6A patent/BR112014009069A2/pt not_active Application Discontinuation
- 2012-10-12 CN CN201280061977.3A patent/CN104245732B/zh not_active Expired - Fee Related
- 2012-10-12 UY UY0001034394A patent/UY34394A/es unknown
- 2012-10-12 PT PT127754232T patent/PT2766395T/pt unknown
- 2012-10-12 WO PCT/US2012/059977 patent/WO2013056068A1/en not_active Ceased
- 2012-10-12 HU HUE12775423A patent/HUE048365T2/hu unknown
- 2012-10-12 MX MX2014004293A patent/MX357231B/es active IP Right Grant
-
2013
- 2013-12-10 US US14/101,441 patent/US8981072B2/en active Active
-
2014
- 2014-04-03 IL IL23192514A patent/IL231925B/en active IP Right Grant
- 2014-04-09 ZA ZA2014/02603A patent/ZA201402603B/en unknown
- 2014-04-10 CO CO14078322A patent/CO7020864A2/es unknown
- 2014-04-14 CL CL2014000958A patent/CL2014000958A1/es unknown
- 2014-10-09 US US14/510,474 patent/US9228018B2/en active Active
-
2015
- 2015-11-24 US US14/950,949 patent/US9765150B2/en active Active
-
2016
- 2016-04-28 AU AU2016202717A patent/AU2016202717A1/en not_active Abandoned
-
2017
- 2017-08-03 US US15/668,305 patent/US10196451B2/en active Active
-
2018
- 2018-12-12 US US16/218,077 patent/US11180567B2/en active Active
-
2020
- 2020-02-18 CY CY20201100147T patent/CY1123618T1/el unknown
-
2021
- 2021-11-09 US US17/522,008 patent/US20220073636A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530611A5 (https=) | ||
| JP2014513953A5 (https=) | ||
| JP2017099391A5 (https=) | ||
| HRP20200230T1 (hr) | Polipeptidi antitijela koji antagoniziraju cd40l | |
| JP6548696B2 (ja) | ヒト抗ｉｌ−３３中和モノクローナル抗体 | |
| AU2015232352B2 (en) | Antibody-fynomer conjugates | |
| JP2020521458A5 (https=) | ||
| JP2022507741A5 (https=) | ||
| CN108473563B (zh) | 改进的tnf结合剂 | |
| JP2020124205A (ja) | Ｉｌ−２３ａ及びｔｎｆ−アルファを標的とする化合物ならびにその使用 | |
| JP2010500005A5 (https=) | ||
| JP2014511844A5 (https=) | ||
| TWI797124B (zh) | 抗干擾素-γ之抗體及其應用 | |
| JP2014503209A5 (https=) | ||
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| JP2011506422A5 (https=) | ||
| TW200831533A (en) | Interleukin-13 binding proteins | |
| RU2007142444A (ru) | Улучшенные нанотела против фактора некроза опухоли-альфа | |
| IL291571B1 (en) | CX3CR1 binding polypeptides | |
| TR201802225T4 (tr) | IL-4 ve/veya IL-13 bağlayan antikorlar ve bunların kullanımı. | |
| WO2015137843A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| JP7189211B2 (ja) | 血清中のタンパク質の半減期を増加させるための組成物及び方法 | |
| TW201233795A (en) | Chemokine receptor binding polypeptides | |
| KR101646830B1 (ko) | Ｂ형 간염 바이러스를 중화시킬 수 있는 결합 분자 | |
| JP2011518857A5 (https=) |